ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler: Affiliates Receives Additional NIAID Funding to Advance Pharmaceutical Development

06/08/2021 | 03:31am EDT

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract
Eckert & Ziegler: Affiliates Receives Additional NIAID Funding to Advance Pharmaceutical Development

08.06.2021 / 09:30
The issuer is solely responsible for the content of this announcement.


Berlin, 8 June 2021 - Myelo Therapeutics GmbH, an affiliate of Eckert & Ziegler (ISIN DE0005659700, TecDAX) focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, extended their contract to advance the development of the new chemical entity Myelo001. The extension into year two of the three-year contract provides an additional $2 million to Myelo Therapeutics to develop clinical-stage Myelo001 as an oral formulation MCM for the treatment of Hematopoietic Acute Radiation Syndrome (H-ARS). The total contract, initially awarded in April 2020, is valued at up to $ 6.2 million over three years if all options are exercised.

The additional funds will advance the development of Myelo001 as an H-ARS monotherapy, and in polypharmacy regimens in laboratory models ranging from rodents to larger animals toward an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA). The candidate MCM development program is funded in whole or in part by the Radiation and Nuclear Countermeasures Program (RNCP), NIAID, part of the National Institutes of Health (NIH), in the Department of Health, and Human Services (HHS), under Contract No. 75N93020C00005. Only a select number of companies are funded by the RNCP, based on a highly competitive application process.

About Acute Radiation Syndrome
ARS, also known as radiation toxicity or radiation sickness, is an acute illness that presents after exposure of large portions of the body to high levels of radiation, like those that might be experienced during a radiological or nuclear incident. The primary manifestation of ARS is the depletion of hematopoietic stem and progenitor cells, constituting one of the major causes of mortality. The U.S. government encourages development of new drugs to treat bodily injuries resulting from ARS.

About Myelo Therapeutics
Myelo Therapeutics is a pharmaceutical company based in Berlin, Germany, that is developing innovative treatments in areas of high unmet medical needs, such as Chemotherapy-Induced Myelosuppression (CIM), Radiation-Induced Myelosuppression (RIM), and ARS. Myelo's lead candidate, Myelo001 is a clinical-stage, adjuvant cancer therapy for treatment of chemotherapy - and radiotherapy-induced myelosuppression. It is delivered as an oral tablet formulation and is stable at room temperature for at least three years. Preclinical and clinical studies have shown that Myelo001 has both prophylactic and therapeutic efficacy at reducing hematopoietic symptoms caused by radiation and chemotherapy. Eckert & Ziegler is one of Myelo's largest shareholder and has funded a substantial portion of the Myelo001 development activities. www.myelotherapeutics.com.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with her 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com



08.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1205436

 
End of News DGAP News Service

1205436  08.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1205436&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reports Earnings Results for the First..
CI
05/12Eckert & Ziegler with Sales Growth in the First Quarter of 2022
EQ
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reaffirms Earnings Guidance for the Ye..
CI
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
EQ
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
CI
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Report of the Supervisory Board
PU
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Proposal on the appropriation of net income
PU
04/11ECKERT & ZIEGLER : Hauck & Aufhauser remains its Buy rating
MD
04/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Hauck & Aufhäuser
PU
04/08ECKERT & ZIEGLER : Radboud University Medical Center Netherlands to Image First Patient wi..
EQ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2022 205 M 216 M 216 M
Net income 2022 30,7 M 32,3 M 32,3 M
Net cash 2022 55,7 M 58,7 M 58,7 M
P/E ratio 2022 28,8x
Yield 2022 1,17%
Capitalization 890 M 938 M 938 M
EV / Sales 2022 4,07x
EV / Sales 2023 3,91x
Nbr of Employees 866
Free-Float 67,1%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 42,90 €
Average target price 152,00 €
Spread / Average Target 254%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar Löffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG-54.41%938
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868